PFE Jun 2024 29.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.7500

+0.0300

(+1.74%)

At close: 02:42PM EDT

Investor's Business Daily
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.
Zacks
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Barrons.com
Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.